<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">HNRNPR Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>HNRNPR</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>HNRNPR</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=HNRNPR" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
HNRNPR (Heterogeneous Nuclear Ribonucleoprotein R) is a gene located on chromosome 1p36.22 that encodes an RNA-binding protein belonging to the heterogeneous nuclear ribonucleoprotein (hnRNP) family. This gene plays critical roles in post-transcriptional gene regulation, including pre-mRNA processing, alternative splicing, mRNA stability, and RNA transport. HNRNPR is expressed throughout the central nervous system and has been increasingly recognized for its involvement in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease[@kim2019].
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">HNRNPR Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>HNRNPR</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>HNRNPR</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=HNRNPR" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
HNRNPR (Heterogeneous Nuclear Ribonucleoprotein R) is a gene located on chromosome 1p36.22 that encodes an RNA-binding protein belonging to the heterogeneous nuclear ribonucleoprotein (hnRNP) family. This gene plays critical roles in post-transcriptional gene regulation, including pre-mRNA processing, alternative splicing, mRNA stability, and RNA transport. HNRNPR is expressed throughout the central nervous system and has been increasingly recognized for its involvement in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), Alzheimer's disease, and Parkinson's disease[@kim2019].
The HNRNPR protein contains multiple RNA recognition motifs (RRMs) that enable it to bind to specific RNA sequences and participate in various aspects of RNA metabolism. Dysregulation of HNRNPR has been linked to altered RNA metabolism observed in neurodegenerative conditions, making it a subject of significant interest in understanding the molecular mechanisms of neuronal death and exploring potential therapeutic targets[@dawson2019].
The HNRNPR gene spans approximately 18.5 kilobases on the short arm of chromosome 1 (1p36.22), a region that has been implicated in various neurological disorders. The gene consists of 15 exons that undergo alternative splicing to generate multiple transcript variants. The gene promoter contains regulatory elements that respond to neuronal activity and stress conditions, allowing dynamic regulation of HNRNPR expression in different physiological and pathological contexts.
The HNRNPR protein is approximately 644 amino acids in length with a molecular weight of around 70 kDa. The protein architecture includes:
HNRNPR plays a central role in the regulation of alternative splicing, a critical mechanism for generating protein diversity in neuronal cells. The protein interacts with components of the spliceosome machinery and modulates the inclusion or exclusion of specific exons in target transcripts. In neurons, HNRNPR-regulated splicing events are particularly important for:
Beyond splicing, HNRNPR regulates mRNA stability by binding to specific elements in the 3' untranslated regions (UTRs) of target mRNAs. The protein can either stabilize or destabilize transcripts depending on the specific RNA binding partners and cellular context. This function is particularly important for:
Neurons rely on localized RNA translation for synaptic plasticity and function. HNRNPR contributes to RNA transport by:
In dendritic processes, HNRNPR-containing granules transport transcripts encoding synaptic proteins, allowing rapid local protein synthesis in response to synaptic activity. This spatial regulation of gene expression is essential for learning, memory formation, and synaptic plasticity[@martinez2016].
HNRNPR has emerged as a significant player in ALS pathogenesis through multiple mechanisms:
Stress Granule Formation: Under cellular stress, HNRNPR localizes to stress granules—membrane-less organelles that sequester RNA-binding proteins and mRNAs. In ALS, dysregulated stress granule dynamics contribute to the formation of toxic protein aggregates. HNNRPR interacts with other ALS-associated proteins including TDP-43 (TARDBP), FUS, and SOD1 in stress granule compartments[@vassallo2020].
RNA Processing Defects: ALS-linked mutations in RNA-binding proteins disrupt normal RNA processing. HNRNPR levels are altered in ALS patient tissue, and the protein exhibits aberrant localization in motor neurons. This contributes to the widespread RNA splicing defects observed in ALS, including dysregulation of genes involved in cytoskeletal function, mitochondrial dynamics, and synaptic transmission[@shi2015].
Nuclear Import/Export Dysfunction: HNRNPR normally shuttles between the nucleus and cytoplasm. In ALS, this transport is disrupted, leading to cytoplasmic accumulation and loss of nuclear function. This nuclear-cytoplasmic transport defect is a common theme in ALS pathogenesis and affects multiple RNA-binding proteins.
Therapeutic Implications: Targeting HNRNPR-mediated RNA processing pathways represents a potential therapeutic strategy for ALS. Approaches being explored include:
Growing evidence links HNRNPR to Alzheimer's disease pathogenesis:
Tau Metabolism: HNRNPR interacts with tau mRNA and regulates its alternative splicing. The protein influences the inclusion of exon 10 in tau transcripts, which determines the ratio of 3R-tau to 4R-tau isoforms. Dysregulation of this process may contribute to tau pathology in AD[@berto2017].
Amyloid Processing: Studies have identified HNRNPR in complexes with amyloid precursor protein (APP) processing machinery. The protein may influence APP splicing and amyloid-beta production, although the exact mechanisms remain under investigation.
Gene Expression Changes: Transcriptomic analyses of AD brain tissue reveal altered HNRNPR expression patterns. Studies have documented decreased HNRNPR levels in hippocampus and cortex of AD patients, correlating with cognitive decline[@zhou2023].
Synaptic Dysfunction: HNRNPR regulates synaptic protein expression, and its dysregulation contributes to synaptic loss—a hallmark of AD pathology. The protein's role in local translation at synapses makes it particularly vulnerable to the translational dysregulation observed in AD.
HNRNPR involvement in Parkinson's disease has been increasingly recognized:
Alpha-Synuclein Regulation: RNA-binding proteins including HNRNPR interact with SNCA mRNA and regulate its translation and splicing. Alterations in this regulation may influence alpha-synuclein expression levels.
Mitochondrial Function: HNRNPR regulates transcripts encoding mitochondrial proteins. Dysregulation contributes to the mitochondrial dysfunction characteristic of PD.
Stress Response: PD-associated stressors including oxidative stress and mitochondrial toxins alter HNRNPR localization and function, potentially exacerbating cellular vulnerability.
Studies have documented HNRNPR expression changes in PD patient brain tissue and experimental models, supporting its role in disease pathogenesis[@bhardwaj2021].
HNRNPR dysregulation has been implicated in:
HNRNPR exhibits widespread expression throughout the central nervous system:
At the cellular level, HNRNPR displays:
HNRNPR expression is dynamically regulated:
HNHNPR as a potential biomarker:
Strategies targeting HNRNPR:
Key challenges in targeting HNRNPR therapeutically:
HNRNPR interacts with numerous proteins in neuronal cells:
HNRNPR is modulated by various signaling pathways:
Key methods for studying HNRNPR:
Research utilizes diverse models:
HNRNPR-containing RNA granules represent dynamic compartments that undergo assembly and disassembly in response to cellular signals. These granules serve multiple functions:
Stress Granules: Under cellular stress (oxidative stress, heat shock, ER stress), HNRNPR rapidly translocates to stress granules. These membrane-less organelles temporarily store翻译ally arrested mRNAs and RNA-binding proteins. In neurodegenerative diseases, stress granule dynamics are disrupted, leading to persistent granules that may nucleate toxic protein aggregates.
Processing Bodies (P-bodies): HNRNPR also localizes to P-bodies, which are involved in mRNA decay and storage. These structures contain decapping enzymes, exonucleases, and RNA-binding proteins. The interplay between stress granules and P-bodies regulates mRNA fate.
Neuronal Granules: In neurons, specialized transport granules mediate dendritic RNA localization. HNRNPR-containing granules traverse dendritic shafts to deliver transcripts to synaptic compartments. Synaptic activity regulates granule dynamics, allowing rapid localized protein synthesis.
HNRNPR can form pathological aggregates through several mechanisms:
Liquid-Liquid Phase Separation (LLPS): HNRNPR's prion-like domain promotes phase separation into liquid droplets. Under pathological conditions, these droplets can transition to solid-like aggregates. This process is enhanced by post-translational modifications and disease-associated mutations.
Co-aggregation with TDP-43: In ALS and FTD, HNRNPR co-aggregates with TDP-43 in cytoplasmic inclusions. This co-aggregation may be mediated by shared RNA targets and direct protein-protein interactions. The formation of mixed aggregates may be more toxic than individual protein aggregates.
Cross-seeding: HNRNPR may be recruited to aggregates of other neurodegenerative disease proteins, including alpha-synuclein in PD and tau in AD. This cross-seeding could propagate protein aggregation in a prion-like manner.
HNRNPR expression and function are regulated by epigenetic mechanisms:
Transcriptional Regulation: HNRNPR promoter contains binding sites for neuronal transcription factors. Activity-dependent signaling pathways (cAMP, calcium) modulate HNRNPR expression through CREB and other response elements.
Post-transcriptional Regulation: microRNAs (miR-9, miR-124) target HNRNPR mRNA, regulating protein levels in neurons. These miRNAs are themselves dysregulated in neurodegenerative diseases.
Post-translational Modifications: HNRNPR undergoes phosphorylation, methylation, and sumoylation. These modifications regulate RNA binding, protein-protein interactions, and subcellular localization. Disease-associated changes in these modifications contribute to HNRNPR dysfunction.
HNHNPR has potential as a diagnostic biomarker:
Cerebrospinal Fluid: HNRNPR fragments can be detected in CSF of patients with ALS, AD, and PD. CSF HNRNPR levels correlate with disease severity and progression. ELISA-based assays are being developed for clinical use.
Blood Biomarkers: Peripheral blood monocyte HNRNPR mRNA levels are altered in neurodegenerative diseases. These changes may reflect central nervous system pathology through immune cell signaling.
Neuroimaging: PET ligands that bind HNRNPR-containing aggregates are under development. These imaging agents could provide information about RNA granule pathology in living patients.
HNRNPR genetic variants have been associated with neurodegenerative disease risk:
GWAS Findings: Genome-wide association studies have identified HNRNPR variants associated with increased risk for ALS, AD, and PD. These variants may affect HNRNPR expression or RNA binding specificity.
Rare Mutations: Exome sequencing has identified rare HNRNPR mutations in familial ALS cases. These mutations are located in the RNA binding domains and likely affect protein function.
Expression QTLs: Expression quantitative trait loci (eQTLs) in the HNRNPR locus influence gene expression. These variants may modify neurodegenerative disease risk through altered HNRNPR levels.
Multiple therapeutic strategies are being developed:
RNA-Targeting Therapies: Antisense oligonucleotides (ASOs) can be designed to:
Small Molecule Modulators: Compound screens have identified small molecules that:
Gene Therapy: Viral vector-mediated delivery of wild-type HNRNPR could restore normal function in patients with loss-of-function mutations. This approach requires careful consideration of appropriate expression levels and cell-type targeting.
Repurposing Existing Drugs: Several FDA-approved drugs affect HNRNPR-related pathways:
HNRNPR is evolutionarily conserved across species:
Vertebrates: Orthologs present in all vertebrate species examined. The protein domain architecture is highly conserved, with >90% identity between human and mouse HNRNPR.
Invertebrates: Drosophila melanogaster has a single ortholog (Hrb87F), and C. elegans has orthologs (hrp-1, hrp-2). These proteins participate in similar RNA processing functions.
Conservation of Disease Mechanisms: Knockout of HNRNPR orthologs in mice and Drosophila reproduces aspects of neurodegenerative disease, validating the relevance of HNRNPR dysfunction.
Important differences exist between species:
Expression Patterns: Rodent HNRNPR shows some brain region-specific differences compared to humans. These differences may affect the translational value of animal models.
Protein Isoforms: Alternative splicing generates species-specific isoforms. The functional significance of these differences is under investigation.
Important questions remain about HNRNPR in neurodegeneration:
New approaches will accelerate research:
Single-cell Multi-omics: Combined measurement of HNRNPR, RNA, and chromatin in individual neurons will reveal cell-type specific dysregulation.
CRISPR Screening: Genome-wide CRISPR screens will identify genes that modify HNRNPR toxicity.
Organoid Models: Brain organoids derived from patient iPSCs will provide human-relevant model systems.